Source-grounded facts extracted from Surgery Partners, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Surgery Partners, Inc. reported Full year 2026 results: revenue $3.35 billion to $3.45 billion. Guidance reaffirmed.
“The Company reaffirmed its outlook for 2026 revenues to be in the range of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million.”
Surgery Partners, Inc. reported first quarter ended March 31, 2026 results: revenue $810.9 million, net income $35.9 million. Guidance reaffirmed.
“return the business to consistent growth, while delivering on long-term shareholder value.” First Quarter 2026 Results Revenues for the first quarter of 2026 increased 4.5% to $810.9 million compared to $776.0 million for the first quarter of 2025. Same-facility revenues for the first quarter of 2026 increased 4.4% as compared to the same period in prior year, with a”
Surgery Partners, Inc. incurred senior notes of $425.0 million at 7.250% maturing due 2032.
“issued an additional $425.0 million aggregate principal amount of 7.250% Senior Notes due 2032”
Surgery Partners, Inc. incurred credit facility of Aggregate principal amount of $1,383 million for 2025 Refinancing Term Loans; revolving credit commitments refinanced in with Jefferies Finance LLC and other financial institutions at Term SOFR plus 2.50% per annum or alternate base rate plus 1.50% per annum maturing December 19, 2030 for term loans; December 19, 2028 for revolving loans.
“The Second Amendment amended the Credit Agreement to, among other things, (i) provide for a new tranche of term loans under the Credit Agreement in an aggregate principal amount of $1,383 million (the “2025 Refinancing Term Loans”), which 2025 Refinancing Term Loans replace or refinance in full all of the existing term loans outstanding under the Credit Agreement (as in effect immediately prior to the Second Amendment), and (ii) refinance in full all of the existing revolving credit commitments and outstanding revolving loans under the Credit Agreement (as in effect immediately prior to the Second Amendment), all as further set forth in the Second Amendment.”
Surgery Partners, Inc. reported full year 2024 results: revenue at least $3.05 billion. Guidance raised.
“The Company raised its outlook for 2024 revenues to be at least $3.05 billion and projects 2024 Adjusted EBITDA to be at least $505 million.”
Surgery Partners, Inc. reported three months ended March 31, 2024 results: revenue $717.4 million, net income -$12.4 million.
“• Revenues increased 7.7% to $717.4 million compared to the prior year period ◦ Same-facility revenues increased 10.2% • Net loss attributable to Surgery Partners, Inc. was $12.4 million”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.